Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T.

J Cyst Fibros. 2019 Jul 11. pii: S1569-1993(19)30815-X. doi: 10.1016/j.jcf.2019.06.011. [Epub ahead of print]

PMID:
31303382
2.

Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.

Drevinek P, Pressler T, Cipolli M, De Boeck K, Schwarz C, Bouisset F, Boff M, Henig N, Paquette-Lamontagne N, Montgomery S, Perquin J, Tomkinson N, den Hollander W, Elborn JS.

J Cyst Fibros. 2019 Jun 7. pii: S1569-1993(19)30766-0. doi: 10.1016/j.jcf.2019.05.014. [Epub ahead of print]

3.

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).

Davies JC, Van de Steen O, van Koningsbruggen-Rietschel S, Drevinek P, Derichs N, McKone EF, Kanters D, Allamassey L, Namour F, de Kock H, Conrath K.

J Cyst Fibros. 2019 May 27. pii: S1569-1993(19)30111-0. doi: 10.1016/j.jcf.2019.05.006. [Epub ahead of print]

4.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K.

J Cyst Fibros. 2019 May 2. pii: S1569-1993(19)30073-6. doi: 10.1016/j.jcf.2019.04.014. [Epub ahead of print]

5.

Microbiological diagnostics of bloodstream infections in Europe-an ESGBIES survey.

Idelevich EA, Seifert H, Sundqvist M, Scudeller L, Amit S, Balode A, Bilozor A, Drevinek P, Kocak Tufan Z, Koraqi A, Lamy B, Mareković I, Miciuleviciene J, Müller Premru M, Pascual A, Pournaras S, Saegeman V, Schønheyder HC, Schrenzel J, Strateva T, Tilley R, Wiersinga WJ, Zabicka D, Carmeli Y, Becker K; ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES).

Clin Microbiol Infect. 2019 Apr 10. pii: S1198-743X(19)30143-0. doi: 10.1016/j.cmi.2019.03.024. [Epub ahead of print]

PMID:
30980927
6.

The use of broad-range bacterial PCR in the diagnosis of infectious diseases: a prospective cohort study.

Tkadlec J, Peckova M, Sramkova L, Rohn V, Jahoda D, Raszka D, Berousek J, Mosna F, Vymazal T, Kvapil M, Drevinek P.

Clin Microbiol Infect. 2019 Jun;25(6):747-752. doi: 10.1016/j.cmi.2018.10.001. Epub 2018 Oct 12.

PMID:
30321604
7.

Attack of the clones: whole genome-based characterization of two closely related enterohemorrhagic Escherichia coli O26 epidemic lineages.

Karnisova L, Marejkova M, Hrbackova H, Mellmann A, Karch H, Fruth A, Drevinek P, Blahova K, Bielaszewska M, Nunvar J.

BMC Genomics. 2018 Aug 31;19(1):647. doi: 10.1186/s12864-018-5045-7.

8.

Bloodstream infection caused by Bacteroides denticanum, a close relative of Bacteroides pyogenes, misidentified by MALDI TOF- mass spectrometry.

Tkadlec J, Krutova M, Matejkova J, Nyc O, Drevinek P.

Anaerobe. 2018 Dec;54:23-25. doi: 10.1016/j.anaerobe.2018.06.010. Epub 2018 Jul 11.

PMID:
30006318
9.

Insights into the cystic fibrosis care in Eastern Europe: Results of survey.

Walicka-Serzysko K, Peckova M, Noordhoek JJ, Sands D, Drevinek P.

J Cyst Fibros. 2018 Jul;17(4):475-477. doi: 10.1016/j.jcf.2018.04.003. Epub 2018 Apr 19.

PMID:
29681443
10.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

11.

What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics.

Nunvar J, Capek V, Fiser K, Fila L, Drevinek P.

PLoS Pathog. 2017 Dec 11;13(12):e1006762. doi: 10.1371/journal.ppat.1006762. eCollection 2017 Dec.

12.

Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.

Kramná L, Dřevínek P, Lin J, Kulich M, Cinek O.

Folia Microbiol (Praha). 2018 Mar;63(2):237-248. doi: 10.1007/s12223-017-0562-3. Epub 2017 Nov 10.

PMID:
29127619
13.

Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015.

Krutova M, Matejkova J, Drevinek P, Kuijper EJ, Nyc O; study group.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2251-2258. doi: 10.1007/s10096-017-3055-z. Epub 2017 Jul 5.

PMID:
28681203
14.

Burkholderia cepacia complex in cystic fibrosis in the post-epidemic period: multilocus sequence typing-based approach.

Fila L, Dřevínek P.

Folia Microbiol (Praha). 2017 Nov;62(6):509-514. doi: 10.1007/s12223-017-0523-x. Epub 2017 Mar 31.

PMID:
28364392
15.

Sequential Burkholderia cenocepacia Isolates from Siblings with Cystic Fibrosis Show Increased Lung Cell Attachment.

Cullen L, O'Connor A, Drevinek P, Schaffer K, McClean S.

Am J Respir Crit Care Med. 2017 Mar 15;195(6):832-835. doi: 10.1164/rccm.201607-1360LE. No abstract available.

PMID:
28294652
16.

Acetic acid is elevated in the exhaled breath of cystic fibrosis patients.

Španěl P, Sovová K, Dryahina K, Doušová T, Dřevínek P, Smith D.

J Cyst Fibros. 2017 Sep;16(5):e17-e18. doi: 10.1016/j.jcf.2017.02.001. Epub 2017 Feb 16. No abstract available.

PMID:
28215621
17.

A case report of a cochlear implant infection - A reason to explant the device?

Skrivan J, Drevinek P.

Cochlear Implants Int. 2016 Sep;17(5):246-249. Epub 2016 Sep 9.

PMID:
27609547
18.

Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection?

Španěl P, Sovová K, Dryahina K, Doušová T, Dřevínek P, Smith D.

J Breath Res. 2016 Aug 17;10(3):036013. doi: 10.1088/1752-7155/10/3/036013.

PMID:
27532768
19.

Understanding the Pathogenicity of Burkholderia contaminans, an Emerging Pathogen in Cystic Fibrosis.

Nunvar J, Kalferstova L, Bloodworth RA, Kolar M, Degrossi J, Lubovich S, Cardona ST, Drevinek P.

PLoS One. 2016 Aug 11;11(8):e0160975. doi: 10.1371/journal.pone.0160975. eCollection 2016.

20.

Clostridium difficile PCR ribotypes 001 and 176 - the common denominator of C. difficile infection epidemiology in the Czech Republic, 2014.

Krutova M, Matejkova J, Kuijper EJ, Drevinek P, Nyc O; Czech Clostridium difficile study group.

Euro Surveill. 2016 Jul 21;21(29). doi: 10.2807/1560-7917.ES.2016.21.29.30296.

21.

Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up.

Fila L, Valentova Bartakova L, Grandcourtova A, Marel M, Drnek R, Bilkova A, Macek M, Drevinek P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):276-9. doi: 10.5507/bp.2016.029. Epub 2016 May 25.

22.

Breath concentration of acetic acid vapour is elevated in patients with cystic fibrosis.

Smith D, Sovová K, Dryahina K, Doušová T, Dřevínek P, Španěl P.

J Breath Res. 2016 May 17;10(2):021002. doi: 10.1088/1752-7155/10/2/021002.

PMID:
27184114
23.

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.

Mlčoch T, Klimeš J, Fila L, Vávrová V, Skalická V, Turnovec M, Krulišová V, Jirčíková J, Zemková D, Dědečková KV, Bílková A, Frühaufová V, Homola L, Friedmannová Z, Drnek R, Dřevínek P, Doležal T, Macek M Jr.

Eur J Health Econ. 2017 Jan;18(1):73-82. doi: 10.1007/s10198-015-0759-9. Epub 2016 Jan 7.

PMID:
26743971
24.

How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.

Kalferstova L, Vilimovska Dedeckova K, Antuskova M, Melter O, Drevinek P.

J Hosp Infect. 2016 Jan;92(1):54-60. doi: 10.1016/j.jhin.2015.09.010. Epub 2015 Oct 8.

PMID:
26597636
25.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

26.

Identification of bacteria from aerobic and anaerobic blood cultures after short cultivation by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry.

Nunvar J, Drevinek P.

J Med Microbiol. 2015 Oct;64(10):1253-5. doi: 10.1099/jmm.0.000140. Epub 2015 Jul 17. No abstract available.

PMID:
26297327
27.

Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.

Cullen L, Weiser R, Olszak T, Maldonado RF, Moreira AS, Slachmuylders L, Brackman G, Paunova-Krasteva TS, Zarnowiec P, Czerwonka G, Reilly J, Drevinek P, Kaca W, Melter O, De Soyza A, Perry A, Winstanley C, Stoitsova SR, Lavigne R, Mahenthiralingam E, Sá-Correia I, Coenye T, Drulis-Kawa Z, Augustyniak D, Valvano MA, McClean S.

Microbiology. 2015 Oct;161(10):1961-77. doi: 10.1099/mic.0.000155. Epub 2015 Aug 6.

PMID:
26253522
28.

Draft Genome Sequences of Burkholderia contaminans, a Burkholderia cepacia Complex Species That Is Increasingly Recovered from Cystic Fibrosis Patients.

Bloodworth RA, Selin C, López De Volder MA, Drevinek P, Galanternik L, Degrossi J, Cardona ST.

Genome Announc. 2015 Aug 6;3(4). pii: e00766-15. doi: 10.1128/genomeA.00766-15.

29.

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade.

Raidt L, Idelevich EA, Dübbers A, Küster P, Drevinek P, Peters G, Kahl BC.

Pediatr Infect Dis J. 2015 Jul;34(7):700-5. doi: 10.1097/INF.0000000000000714.

PMID:
25851069
30.

In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.

Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, de Soyza A, McClean S, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.

31.

Gene expression profiling of Burkholderia cenocepacia at the time of cepacia syndrome: loss of motility as a marker of poor prognosis?

Kalferstova L, Kolar M, Fila L, Vavrova J, Drevinek P.

J Clin Microbiol. 2015 May;53(5):1515-22. doi: 10.1128/JCM.03605-14. Epub 2015 Feb 18.

32.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group.

Lancet Respir Med. 2014 Nov;2(11):902-910. doi: 10.1016/S2213-2600(14)70218-8. Epub 2014 Oct 9.

PMID:
25311995
33.

Possible Tyromyces fissilis (Basidiomycota, Polyporales) co-infection in a lung transplant recipient.

Chrenkova V, Kolarik M, Hubacek P, Kolarik J, Simonek J, Lischke R, Drevinek P.

Folia Microbiol (Praha). 2015 Jan;60(1):33-5. doi: 10.1007/s12223-014-0336-0. Epub 2014 Jul 27.

PMID:
25064474
34.

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D.

J Cyst Fibros. 2014 May;13 Suppl 1:S3-22. doi: 10.1016/j.jcf.2014.03.009. Review.

35.

[Bacteria of the Burkholderia cepacia complex: epidemiology and diagnosis of infection in patients with cystic fibrosis].

Dřevínek P.

Epidemiol Mikrobiol Imunol. 2014 Feb;63(1):18-26. Review. Czech.

PMID:
24730990
36.

Developing an international Pseudomonas aeruginosa reference panel.

De Soyza A, Hall AJ, Mahenthiralingam E, Drevinek P, Kaca W, Drulis-Kawa Z, Stoitsova SR, Toth V, Coenye T, Zlosnik JE, Burns JL, Sá-Correia I, De Vos D, Pirnay JP, Kidd TJ, Reid D, Manos J, Klockgether J, Wiehlmann L, Tümmler B, McClean S, Winstanley C; EU FP7 funded COST Action BM1003 “Cell surface virulence determinants of cystic fibrosis pathogens”.

Microbiologyopen. 2013 Dec;2(6):1010-23. doi: 10.1002/mbo3.141. Epub 2013 Nov 11.

37.

Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.

Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H; ECFS Patient Registry Steering Group.

Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.

38.

Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients.

Dedeckova K, Kalferstova L, Strnad H, Vavrova J, Drevinek P.

J Cyst Fibros. 2013 Sep;12(5):475-81. doi: 10.1016/j.jcf.2012.12.007. Epub 2013 Jan 11.

39.

Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.

Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, Assael BM, Barreto C, Drevinek P, Thomas M, Krivec U, Mei-Zahav M, Vibert JF, Clement A, Mehta A, Corvol H; French CF Modifier Gene Study Investigators; European CF Registry Working Group.

Orphanet J Rare Dis. 2012 Sep 7;7:64. doi: 10.1186/1750-1172-7-64.

40.

PCR detection of Burkholderia cepacia complex as one of key factors to handle a long-term outbreak.

Dedeckova K, Fila L, Skalicka V, Bartosova J, Kucerova T, Vavrova V, Zemkova D, Kalferstova L, Melter O, Cinek O, Drevinek P.

J Cyst Fibros. 2012 Sep;11(5):440-5. doi: 10.1016/j.jcf.2012.04.005. Epub 2012 May 22.

41.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group.

N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.

42.

DNA profiling of Stenotrophomonas maltophilia by PCR targeted to its species-specific repetitive palindromic sequences.

Nunvar J, Drevinek P, Licha I.

Lett Appl Microbiol. 2012 Jan;54(1):59-66. doi: 10.1111/j.1472-765X.2011.03172.x. Epub 2011 Nov 23.

43.

Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry.

Shestivska V, Nemec A, Dřevínek P, Sovová K, Dryahina K, Spaněl P.

Rapid Commun Mass Spectrom. 2011 Sep 15;25(17):2459-67. doi: 10.1002/rcm.5146.

PMID:
21818806
44.

Recommendations for the classification of diseases as CFTR-related disorders.

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C.

J Cyst Fibros. 2011 Jun;10 Suppl 2:S86-102. doi: 10.1016/S1569-1993(11)60014-3.

45.

Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence.

Drevinek P, Mahenthiralingam E.

Clin Microbiol Infect. 2010 Jul;16(7):821-30. doi: 10.1111/j.1469-0691.2010.03237.x. Review.

46.

Direct culture-independent Strain typing of Burkholderia cepacia complex in sputum samples from patients with cystic fibrosis.

Drevinek P, Vosahlikova S, Dedeckova K, Cinek O, Mahenthiralingam E.

J Clin Microbiol. 2010 May;48(5):1888-91. doi: 10.1128/JCM.02359-09. Epub 2010 Feb 24.

47.

Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption.

Mahenthiralingam E, Marchbank A, Drevinek P, Garaiova I, Plummer S.

BMC Microbiol. 2009 Dec 7;9:251. doi: 10.1186/1471-2180-9-251.

48.

Oxidative stress of Burkholderia cenocepacia induces insertion sequence-mediated genomic rearrangements that interfere with macrorestriction-based genotyping.

Drevinek P, Baldwin A, Lindenburg L, Joshi LT, Marchbank A, Vosahlikova S, Dowson CG, Mahenthiralingam E.

J Clin Microbiol. 2010 Jan;48(1):34-40. doi: 10.1128/JCM.01433-09. Epub 2009 Nov 4.

49.

Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease.

Balascaková M, Holubová A, Skalická V, Zemková D, Kracmar P, Gonsorcíkova L, Camajová J, Piskácková T, Lebl J, Drevínek P, Gregor V, Vávrová V, Votava F, Macek M Jr.

J Cyst Fibros. 2009 May;8(3):224-7. doi: 10.1016/j.jcf.2009.01.002. Epub 2009 Feb 8.

50.

Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum.

Drevinek P, Holden MT, Ge Z, Jones AM, Ketchell I, Gill RT, Mahenthiralingam E.

BMC Infect Dis. 2008 Sep 19;8:121. doi: 10.1186/1471-2334-8-121.

Supplemental Content

Loading ...
Support Center